I write to impart some good news. As the professional regulator for nurses and midwives in Ireland we are eager to embrace and drive positive change within the system that will make us more accessible and also make the necessary interactions that registrants, HEIs, applicants, candidates and graduates have with us faster and easier to manage. In this context I am happy to be able to confirm that our new online portal will go live in September 2020.

In advance of the launch of the new online system, its name is something we need to agree on. We thought that as a registrant you might like to contribute to this process.

The 98th edition of the HPRA Drug Safety Newsletter includes information on the following medicines:

• Adverse reaction reporting during the COVID-19 pandemic – reminder
• Picato (ingenol mebutate) – EMA review concludes negative benefit risk balance due to risk of skin malignancy
• Levetiracetam – risk of abnormal and aggressive behaviours
• Cyproterone acetate – restrictions in use due to risk of meningioma
• Carbimazole and propylthiouracil – use in pregnancy and in women of childbearing potential
• Carbimazole – risk of acute pancreatitis
• Testosterone-containing medicinal products: caution in patients with thrombophilia or risk factors for venous thromboembolism (VTE).

Maura OSullivan with her daughter Ciara O'Sullivan (RPN)